| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 80, 952-957, Copyright © 1995 by Endocrine Society
ARTICLES |
CF Deacon, AH Johnsen and JJ Holst
Department of Medical Physiology, Panum Institute, University of Copenhagen, Denmark.
The metabolism of glucagon-like peptide-1 (GLP-1) has not been studied in detail, but it is known to be rapidly cleared from the circulation. Measurement by RIA is hampered by the fact that most antisera are side- viewing or C-terminally directed, and recognize both intact GLP-1 and biologically inactive. N-terminally truncated fragments. Using high pressure liquid chromatography in combination with RIAs, methodology allowing specific determination of both intact GLP-1 and its metabolites was developed. Human plasma was shown to degrade GLP-1-(7- 36)amide, forming an N-terminally truncated peptide with a t1/2 of 20.4 +/- 1.4 min at 37 C (n = 6). This was unaffected by EDTA or aprotinin. Inhibitors of dipeptidyl peptidase-IV or low temperature (4 C) completely prevented formation of the metabolite, which was confirmed to be GLP-1-(9-36)amide by mass spectrometry and sequence analysis. High pressure liquid chromatography revealed the concentration of GLP-1- (9-36)amide to be 53.5 +/- 13.7% of the concentration of endogenous intact GLP-1 in the fasted state, which increased to 130.8 +/- 10.0% (P < 0.01; n = 6) 1 h postprandially. Metabolism at the C-terminus was not observed. This study suggests that dipeptidyl peptidase-IV is the primary mechanism for GLP-1 degradation in human plasma in vitro and may have a role in inactivating the peptide in vivo.
This article has been cited by other articles:
![]() |
K. Ban, M. H. Noyan-Ashraf, J. Hoefer, S.-S. Bolz, D. J. Drucker, and M. Husain Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor-Dependent and -Independent Pathways Circulation, May 6, 2008; 117(18): 2340 - 2350. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-J. Kim, C. Nian, D. J. Doudet, and C. H.S. McIntosh Inhibition of Dipeptidyl Peptidase IV With Sitagliptin (MK0431) Prolongs Islet Graft Survival in Streptozotocin-Induced Diabetic Mice Diabetes, May 1, 2008; 57(5): 1331 - 1339. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Q. Pham, A. Nogid, and R. Plakogiannis Sitagliptin: A novel agent for the management of type 2 diabetes mellitus Am. J. Health Syst. Pharm., March 15, 2008; 65(6): 521 - 531. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Lu, Q. Yang, W. Sun, S. C. Woods, D. D'Alessio, and P. Tso The regulation of the lymphatic secretion of glucagon-like peptide-1 (GLP-1) by intestinal absorption of fat and carbohydrate Am J Physiol Gastrointest Liver Physiol, November 1, 2007; 293(5): G963 - G971. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Holst The Physiology of Glucagon-like Peptide 1 Physiol Rev, October 1, 2007; 87(4): 1409 - 1439. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Meier, J. J. Holst, W. E. Schmidt, and M. A. Nauck Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E849 - E856. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Drucker Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes: Preclinical biology and mechanisms of action Diabetes Care, June 1, 2007; 30(6): 1335 - 1343. [Full Text] [PDF] |
||||
![]() |
J. S. Freeman The Pathophysiologic Role of Incretins J Am Osteopath Assoc, May 1, 2007; 107(suppl_3): S6 - S9. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Boyle and J. S. Freeman Application of Incretin Mimetics and Dipeptidyl Peptidase IV Inhibitors in Managing Type 2 Diabetes Mellitus J Am Osteopath Assoc, May 1, 2007; 107(suppl_3): S10 - S16. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Vilsboll and F. K Knop Review: DPP IV inhibitors - current evidence and future directions The British Journal of Diabetes & Vascular Disease, March 1, 2007; 7(2): 69 - 74. [Abstract] [PDF] |
||||
![]() |
K. V. Tarbell, L. Petit, X. Zuo, P. Toy, X. Luo, A. Mqadmi, H. Yang, M. Suthanthiran, S. Mojsov, and R. M. Steinman Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice J. Exp. Med., January 22, 2007; 204(1): 191 - 201. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Raun, P. von Voss, C. F. Gotfredsen, V. Golozoubova, B. Rolin, and L. B. Knudsen Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not Diabetes, January 1, 2007; 56(1): 8 - 15. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-L. He, A. Horowitz, C. E. Watson, J. E. Foley, W. Sallas, and M. Ligueros-Saylan Vildagliptin Does Not Affect C-Peptide Clearance in Patients With Type 2 Diabetes J. Clin. Pharmacol., January 1, 2007; 47(1): 127 - 131. [Full Text] [PDF] |
||||
![]() |
B. Charbonnel, A. Karasik, J. Liu, M. Wu, G. Meininger, and for the Sitagliptin Study 020 Group Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone Diabetes Care, December 1, 2006; 29(12): 2638 - 2643. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Parker, K S Lavery, N Irwin, B D Green, B Greer, P Harriott, F P M O'Harte, V A Gault, and P R Flatt Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice. J. Endocrinol., October 1, 2006; 191(1): 93 - 100. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ryskjaer, C. F Deacon, R. D Carr, T. Krarup, S. Madsbad, J. Holst, and T. Vilsboll Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake Eur. J. Endocrinol., September 1, 2006; 155(3): 485 - 493. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Deacon, A. Plamboeck, M. M. Rosenkilde, J. de Heer, and J. J. Holst GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E468 - E475. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Green, K. S. Lavery, N. Irwin, F. P. M. O'Harte, P. Harriott, B. Greer, C. J. Bailey, and P. R. Flatt Novel Glucagon-Like Peptide-1 (GLP-1) Analog (Val8)GLP-1 Results in Significant Improvements of Glucose Tolerance and Pancreatic beta-Cell Function after 3-Week Daily Administration in Obese Diabetic (ob/ob) Mice J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 914 - 921. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Drucker Enhancing the action of incretin hormones: a new whey forward? Endocrinology, July 1, 2006; 147(7): 3171 - 3172. [Full Text] [PDF] |
||||
![]() |
J. J. Meier, A. Gethmann, M. A. Nauck, O. Gotze, F. Schmitz, C. F. Deacon, B. Gallwitz, W. E. Schmidt, and J. J. Holst The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans Am J Physiol Endocrinol Metab, June 1, 2006; 290(6): E1118 - E1123. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Schou, K. Pilgaard, T. Vilsboll, C. B. Jensen, C. F. Deacon, J. J. Holst, A. Volund, S. Madsbad, and A. A. Vaag Normal Secretion and Action of the Gut Incretin Hormones Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Young Men with Low Birth Weight J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4912 - 4919. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ahren and T. E. Hughes Inhibition of Dipeptidyl Peptidase-4 Augments Insulin Secretion in Response to Exogenously Administered Glucagon-Like Peptide-1, Glucose-Dependent Insulinotropic Polypeptide, Pituitary Adenylate Cyclase-Activating Polypeptide, and Gastrin-Releasing Peptide in Mice Endocrinology, April 1, 2005; 146(4): 2055 - 2059. [Abstract] [Full Text] [PDF] |
||||
![]() |
G Uckaya, P Delagrange, A Chavanieu, G Grassy, M-F Berthault, A Ktorza, E Cerasi, G Leibowitz, and N Kaiser Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue J. Endocrinol., March 1, 2005; 184(3): 505 - 513. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Holst and C. Orskov The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism Diabetes, December 1, 2004; 53(suppl_3): S197 - S204. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Deacon Therapeutic Strategies Based on Glucagon-Like Peptide 1 Diabetes, September 1, 2004; 53(9): 2181 - 2189. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Baggio, Q. Huang, T. J. Brown, and D. J. Drucker A Recombinant Human Glucagon-Like Peptide (GLP)-1-Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor-Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis Diabetes, September 1, 2004; 53(9): 2492 - 2500. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Trebbien, L. Klarskov, M. Olesen, J. J. Holst, R. D. Carr, and C. F. Deacon Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E431 - E438. [Abstract] [Full Text] [PDF] |
||||
![]() |
C M. B Edwards GLP-1: target for a new class of antidiabetic agents? J R Soc Med, June 1, 2004; 97(6): 270 - 274. [Full Text] [PDF] |
||||
![]() |
S. Madsbad, O. Schmitz, J. Ranstam, G. Jakobsen, and D. R. Matthews Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial Diabetes Care, June 1, 2004; 27(6): 1335 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ahren, M. Landin-Olsson, P.-A. Jansson, M. Svensson, D. Holmes, and A. Schweizer Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2078 - 2084. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. T. Bloomgarden Glycemic Treatment: Control of glycemia Diabetes Care, May 1, 2004; 27(5): 1227 - 1234. [Full Text] [PDF] |
||||
![]() |
J. J. Meier, O. Goetze, J. Anstipp, D. Hagemann, J. J. Holst, W. E. Schmidt, B. Gallwitz, and M. A. Nauck Gastric inhibitory polypeptide does not inhibit gastric emptying in humans Am J Physiol Endocrinol Metab, April 1, 2004; 286(4): E621 - E625. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Meier, M. A. Nauck, D. Kranz, J. J. Holst, C. F. Deacon, D. Gaeckler, W. E. Schmidt, and B. Gallwitz Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects Diabetes, March 1, 2004; 53(3): 654 - 662. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ahren, J. J. Holst, and A. Mari Characterization of GLP-1 Effects on {beta}-Cell Function After Meal Ingestion in Humans Diabetes Care, October 1, 2003; 26(10): 2860 - 2864. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Drucker Enhancing Incretin Action for the Treatment of Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2929 - 2940. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. K. Knop, T. Vilsboll, S. Larsen, S. Madsbad, J. J. Holst, and T. Krarup No Hypoglycemia After Subcutaneous Administration of Glucagon-Like Peptide-1 in Lean Type 2 Diabetic Patients and in Patients With Diabetes Secondary to Chronic Pancreatitis Diabetes Care, September 1, 2003; 26(9): 2581 - 2587. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Deacon, M. Kelstrup, R. Trebbien, L. Klarskov, M. Olesen, and J. J. Holst Differential regional metabolism of glucagon in anesthetized pigs Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E552 - E560. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Aziz and G. H. Anderson Exendin-4, a GLP-1 Receptor Agonist, Interacts with Proteins and Their Products of Digestion to Suppress Food Intake in Rats J. Nutr., July 1, 2003; 133(7): 2326 - 2330. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Vilsboll, T. Krarup, J. Sonne, S. Madsbad, A. Volund, A. G. Juul, and J. J. Holst Incretin Secretion in Relation to Meal Size and Body Weight in Healthy Subjects and People with Type 1 and Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2706 - 2713. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Conarello, Z. Li, J. Ronan, R. S. Roy, L. Zhu, G. Jiang, F. Liu, J. Woods, E. Zycband, D. E. Moller, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance PNAS, May 27, 2003; 100(11): 6825 - 6830. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Vahl, B. W. Paty, B. D. Fuller, R. L. Prigeon, and D. A. D'Alessio Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on Intravenous Glucose Tolerance and Glucose-Induced Insulin Secretion in Healthy Humans J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1772 - 1779. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Quddusi, T. P. Vahl, K. Hanson, R. L. Prigeon, and D. A. D'Alessio Differential Effects of Acute and Extended Infusions of Glucagon-Like Peptide-1 on First- and Second-Phase Insulin Secretion in Diabetic and Nondiabetic Humans Diabetes Care, March 1, 2003; 26(3): 791 - 798. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Vilsboll, H. Agerso, T. Krarup, and J. J. Holst Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 220 - 224. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Rolin, M. O. Larsen, C. F. Gotfredsen, C. F. Deacon, R. D. Carr, M. Wilken, and L. B. Knudsen The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta -cell mass in diabetic mice Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E745 - E752. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ahren, E. Simonsson, H. Larsson, M. Landin-Olsson, H. Torgeirsson, P.-A. Jansson, M. Sandqvist, P. Bavenholm, S. Efendic, J. W. Eriksson, et al. Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes Diabetes Care, May 1, 2002; 25(5): 869 - 875. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Aziz and G. H. Anderson Exendin-4, a GLP-1 Receptor Agonist, Modulates the Effect of Macronutrients on Food Intake by Rats J. Nutr., May 1, 2002; 132(5): 990 - 995. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Larsen, C. Fledelius, L. B. Knudsen, and M. Tang-Christensen Systemic Administration of the Long-Acting GLP-1 Derivative NN2211 Induces Lasting and Reversible Weight Loss in Both Normal and Obese Rats Diabetes, November 1, 2001; 50(11): 2530 - 2539. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-B. Toft-Nielsen, M. B. Damholt, S. Madsbad, L. M. Hilsted, T. E. Hughes, B. K. Michelsen, and J. J. Holst Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3717 - 3723. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Deacon, P. Danielsen, L. Klarskov, M. Olesen, and J. J. Holst Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs Diabetes, July 1, 2001; 50(7): 1588 - 1597. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zander, M. Taskiran, M.-B. Toft-Nielsen, S. Madsbad, and J. J. Holst Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes Diabetes Care, April 1, 2001; 24(4): 720 - 725. [Abstract] [Full Text] |
||||
![]() |
T. Vilsbøll, T. Krarup, C. F. Deacon, S. Madsbad, and J. J. Holst Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients Diabetes, March 1, 2001; 50(3): 609 - 613. [Abstract] [Full Text] |
||||
![]() |
D. J. Drucker Minireview: The Glucagon-Like Peptides Endocrinology, February 1, 2001; 142(2): 521 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Deacon, M. A. Nauck, J. Meier, K. Hücking, and J. J. Holst Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetic Subjects as Revealed Using a New Assay for the Intact Peptide J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3575 - 3581. [Abstract] [Full Text] |
||||
![]() |
B. Balkan and X. Li Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2000; 279(4): R1449 - R1454. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Hartmann, M. B. Harr, P. B. Jeppesen, M. Wojdemann, C. F. Deacon, P. B. Mortensen, and J. J. Holst In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2884 - 2888. [Abstract] [Full Text] |
||||
![]() |
L. Hansen, B. Hartmann, T. Bisgaard, H. Mineo, P. N. Jorgensen, and J. J. Holst Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum Am J Physiol Endocrinol Metab, June 1, 2000; 278(6): E1010 - E1018. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Xiao, R. P. Boushey, M. Cino, D. J. Drucker, and P. L. Brubaker Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2000; 278(4): R1057 - R1063. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Tavares, D. J. Drucker, and P. L. Brubaker Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats Am J Physiol Endocrinol Metab, January 1, 2000; 278(1): E134 - E139. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text] |
||||
![]() |
L. Hansen, C. F. Deacon, C. Ørskov, and J. J. Holst Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine Endocrinology, November 1, 1999; 140(11): 5356 - 5363. [Abstract] [Full Text] |
||||